Media coverage
26Media coverage
Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet Biotechgate Country Switzerland Date 12/8/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet Canadian Life Sciences Database Country Switzerland Date 12/8/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet PR Newswire Country United States Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet Canada NewsWire Country Canada Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet Global English (Middle East and North Africa Financial Network) Country Jordan Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet PR Newswire Country United States Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet Canada NewsWire Country Canada Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet PR Newswire Country United States Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet Morningstar.com Country United States Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet India Pharma News Country India Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet Finanzen.ch Country Switzerland Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet StocksNewsFeed.com Country United States Date 12/7/19 Persons Ruben Mesa Title SIERRA ONCOLOGY : Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet MarketScreener.com Country United States Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion R Media name/outlet ADVFN Deutschland Country Germany Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet TickerTech.com Country United States Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet Markets Business Insider Country United States Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet Spoke.com Country United States Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet Crwe World Country United States Date 12/7/19 Persons Ruben Mesa Title $SRRA Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet OTC Dynamics Country Canada Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly... Media name/outlet Epicos.com Country Greece Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet ProfitQuotes.com Country United States Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet Channel 8 Eyewitness News Country United States Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet Erie News Now Country United States Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet WICZ Country United States Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet VB Profiles Country United States Date 12/7/19 Persons Ruben Mesa Title Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting Media name/outlet Central Charts Country France Date 12/7/19 Persons Ruben Mesa